ArticleFrontiers in public health2024
Tracking multidrug resistant tuberculosis: a 30-year analysis of global, regional, and national trends.
Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence and contributing factors of drug-resistant tuberculosis (DR-TB) in iran: a systematic review.BMC infectious diseases · 2025Pooled it
- ZILA-SRM: a probabilistic framework with zero-inflated latent models for robust strain reconstruction from metagenomes.Microbiology spectrum · 2026Article
- Burden of multidrug-resistant and extensively drug-resistant tuberculosis in China, India and Russia: estimates from the GBD 2023 study.Journal of thoracic disease · 2026Article
- The epidemiology of tuberculosis infection and the Human Development Index (HDI) in Iran between 1990-2021: secondary analysis of the global burden of disease.BMC infectious diseases · 2026Article
- Burden of Bacterial Antimicrobial Resistance in Libya, 1970-2024: A Systematic Meta-Analysis with Projections to 2050.Antibiotics (Basel, Switzerland) · 2026Review
- Prevalence of drug resistant tuberculosis and its associated factors among tuberculosis patients at wolkite health center in central Ethiopia.Scientific reports · 2026Article
- Multidrug resistant tuberculosis (MDR-TB) in Eritrea: a retrospective cohort analysis of mortality and associated factors (2013 - 2023).Frontiers in cellular and infection microbiology · 2026Article
- Trends and Characteristics of Drug-Resistant Tuberculosis: A Five-Year Study at a Major Specialized Hospital in Guizhou, China (2018-2023).Infection and drug resistance · 2026Article
- How do social network models compare to all-to-all models for forecasting tuberculosis epidemics? A mathematical modeling study.PloS one · 2026Article
- Mixed infections and heteroresistance ofEmerging microbes & infections · 2025Article
- National and sub-national HIV/AIDS epidemiology, socioeconomic influences, and risk factors in Iran from 1990 to 2021, global burden of disease 2021 study.Scientific reports · 2025Article
- Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment.Microorganisms · 2025Review
- Trends and forecast of drug-resistant tuberculosis: a global perspective from the GBD study 2021.Frontiers in public health · 2025Article
- Sociodemographic determinants of multidrug-resistant tuberculosis in Lesotho: A case-control study.PLOS global public health · 2025Article
- Global burden of tuberculosis attributable to diet low in whole grains from 1990 to 2021, with projection to 2045.Frontiers in nutrition · 2025Article
- Applying Multiple Analyses to Quantify Changes in the Global, Regional, and National Burden of Tuberculosis From 1990 to 2021 and the Forecast Until 2035.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- Global trajectory and spatiotemporal epidemiological landscape of multidrug-resistant tuberculosis of spanning 46 years (1990-2035): implications for achieving global end TB goals.Frontiers in public health · 2025Article
- Flavin and deazaflavin biosynthesis in mycobacteria: relevance to physiology, implications for drug discovery, MR-1 antigenicity, and vaccine development.Frontiers in immunology · 2025Review
- Prediction of risk factors associated with the development of multidrug-resistant tuberculosis in patients with tuberculosis.Frontiers in public health · 2025Article
- Global, regional, and national burdens of MDR-TB attributable to smoking from 1990 to 2021 with a prediction from 2022 to 2050.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To provide valuable insights for targeted interventions and resource allocation, our analysis delved into the multifaceted burden, trends, risks, and projections of multi drug resistant tuberculosis (MDR-TB). Methods: This research employed data from the Global Burden of Disease (GBD) 2019 dataset, which used a comparative risk assessment to quantify the disease burden resulting from risk factors. Initially, this database was utilized to extract details concerning the disability-adjusted life years (DALYs), mortality, incidence, and the number of individuals afflicted by MDR-TB. Subsequently, regression analyses were conducted using the Joinpoint program to figure average annual percent change (AAPC) to ascertain the trend. Thirdly, the age-period-cohort model (APCM) was adopted to analyze evolutions in incidence and mortality. Finally, utilizing the Nordpred model within R software, we projected the incidence and mortality of MDR-TB from 2020 to 2030. Results: MDR-TB remained a pressing global health concern in regions with lower socio-demographic indexes (SDI), where the AAPC in DALYs topped 7% from 1990 to 2019. In 2019, the cumulative DALYs attributed to MDR-TB tallied up to 4.2 million, with India, the Russian Federation, and China bearing the brunt. Notably, the incidence rates have shown a steadfast presence over the past decade, and a troubling forecast predicts an uptick in these areas from 2020 to 2030. Additionally, the risk of contracting MDR-TB grew with advancing age, manifesting most acutely among men aged 40+ in lower SDI regions. Strikingly, alcohol consumption had been identified as a significant contributor, surpassing the impacts of smoking and high fasting plasma glucose, leading to 0.7 million DALYs in 2019. Conclusions: A robust strategy is needed to end tuberculosis (TB) by 2030, especially in lower SDI areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.